Clal Biotechnology Industries Ltd

Clal Biotechnology Industries Ltd has a market capitalization of approximately 4.596 billion ILS, with a price-to-book ratio of 227.56, indicating a significant premium to its book value. The company's liquidity position is characterized by a current ratio of 0.14, suggesting a high reliance on short-term financing to meet its obligations. Additionally, the company has a negative net cash position after subtracting total debt, which raises concerns about its short-term liquidity.

In terms of profitability, the company reported a net loss of 13.32 million ILS and an operating loss of 8.47 million ILS, resulting in a negative return on equity of -6.59% and a negative return on assets of -3.18%. These figures are significantly below the industry median for biotechnology firms, which typically exhibit higher returns due to the sector's high-growth potential and R&D intensity.

The company's revenue is concentrated in a single business segment, as it operates primarily as an investment holding company. There is no disclosed geographic diversification in the financial data, and the company's exposure is primarily to the biotechnology sector. This concentration increases the company's vulnerability to sector-specific risks, such as regulatory changes or R&D setbacks.

Looking at the growth trajectory, the company's revenue and earnings have been negative in the most recent reporting period. The company's operating cash flow is also negative, at -3.95 million ILS, and its free cash flow is -19.95 million ILS, indicating a lack of cash generation. These trends suggest a challenging near-term outlook, with no clear signs of improvement in the financial performance.

The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key liquidity flag. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. However, the company's high debt-to-equity ratio of 0.88 suggests a moderate level of financial leverage, which could increase its vulnerability to interest rate fluctuations and economic downturns.

Recent events, as reflected in the financial data, include a reported net loss and a negative operating cash flow. The company's last actual EPS was 0.68 ILS, and its last actual revenue was 117.54 million ILS. These figures indicate a challenging operating environment, with the company failing to generate positive earnings or cash flow from operations.